• Energy Research
• 2025-2025close
• other engineering and technologies close
• GB close
• BE close
• SA close

All over the world, cancer death and prevalence are increasing. Breast cancer (BC) is the major cause of cancer mortality (15%) which makes it the most common cancer in women. BC is defined as the furious progression and quick division of breast cells. Novel nanotechnology-based approaches helped in improving survival rate, metastatic BC is still facing obstacles to treat with an expected overall 23% survival rate. This paper represents epidemiology, classification (non-invasive, invasive and metastatic), risk factors (genetic and non-genetic) and treatment challenges of breast cancer in brief. This review paper focus on the importance of nanotechnology-based nanoformulations for treatment of BC. This review aims to deliver elementary insight and understanding of the novel nanoformulations in BC treatment and to explain to the readers for enduring designing novel nanomedicine. Later, we elaborate on several types of nanoformulations used in tumor therapeutics such as liposomes, dendrimers, polymeric nanomaterials and many others. Potential research opportunities for clinical application and current challenges related to nanoformulations utility for the treatment of BC are also highlighted in this review. The role of artificial intelligence is elaborated in detail. We also confer the existing challenges and perspectives of nanoformulations in effective tumor management, with emphasis on the various patented nanoformulations approved or progression of clinical trials retrieved from various search engines.

In the last decade, the manufacturing capacity of silicon, the dominant PV technology, has increasingly been concentrated in China. This has led to PV cost reduction of approximately 80%, while, at the same time, posing risks to PV supply chain security. Recent advancements of novel perovskite tandem PV technologies as an alternative to traditional silicon-based PV provide opportunities for diversification of the PV manufacturing capacity and for increasing the GHG emission benefit of solar PV. Against this background, we estimate the current and future cost-competitiveness and GHG emissions of a set of already commercialized as well as emerging PV technologies for different production locations (China, USA, EU), both at residential and utility-scale. We find EU and USA-manufactured thin-film tandems to have 2 to 4% and 0.5 to 2% higher costs per kWh and 37 to 40%and 32 to 35% less GHG emissions per kWh at residential and utility-scale, respectively. Our projections indicate that they will also retain competitive costs (up to 2% higher)and a 20% GHG emissions advantage per kWh in 2050.